Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at #ASCO2019; One Patient With Ovarian Cancer Achieved Confirmed Partial Response With Duration of 6.2 Months